AU2014320015B2 - Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution - Google Patents

Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution Download PDF

Info

Publication number
AU2014320015B2
AU2014320015B2 AU2014320015A AU2014320015A AU2014320015B2 AU 2014320015 B2 AU2014320015 B2 AU 2014320015B2 AU 2014320015 A AU2014320015 A AU 2014320015A AU 2014320015 A AU2014320015 A AU 2014320015A AU 2014320015 B2 AU2014320015 B2 AU 2014320015B2
Authority
AU
Australia
Prior art keywords
mvp
solution
thr
gly
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014320015A
Other languages
English (en)
Other versions
AU2014320015A1 (en
Inventor
David Cetlin
Arun Dhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cygnus Technologies LLC
Original Assignee
Cygnus Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Technologies LLC filed Critical Cygnus Technologies LLC
Publication of AU2014320015A1 publication Critical patent/AU2014320015A1/en
Application granted granted Critical
Publication of AU2014320015B2 publication Critical patent/AU2014320015B2/en
Priority to AU2021200484A priority Critical patent/AU2021200484B2/en
Priority to AU2023229501A priority patent/AU2023229501B2/en
Assigned to CYGNUS TECHNOLOGIES, LLC reassignment CYGNUS TECHNOLOGIES, LLC Request for Assignment Assignors: MOCKV SOLUTIONS LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2014320015A 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution Active AU2014320015B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021200484A AU2021200484B2 (en) 2013-09-10 2021-01-27 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution
AU2023229501A AU2023229501B2 (en) 2013-09-10 2023-09-12 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875729P 2013-09-10 2013-09-10
US61/875,729 2013-09-10
PCT/IB2014/064352 WO2015036917A2 (en) 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200484A Division AU2021200484B2 (en) 2013-09-10 2021-01-27 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution

Publications (2)

Publication Number Publication Date
AU2014320015A1 AU2014320015A1 (en) 2016-03-31
AU2014320015B2 true AU2014320015B2 (en) 2020-10-29

Family

ID=52625972

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014320015A Active AU2014320015B2 (en) 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution
AU2021200484A Active AU2021200484B2 (en) 2013-09-10 2021-01-27 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution
AU2023229501A Active AU2023229501B2 (en) 2013-09-10 2023-09-12 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021200484A Active AU2021200484B2 (en) 2013-09-10 2021-01-27 Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution
AU2023229501A Active AU2023229501B2 (en) 2013-09-10 2023-09-12 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Country Status (7)

Country Link
US (4) US9632087B2 (enExample)
EP (1) EP3044339B1 (enExample)
JP (2) JP6549126B2 (enExample)
CN (1) CN105899684B (enExample)
AU (3) AU2014320015B2 (enExample)
DK (1) DK3044339T3 (enExample)
WO (1) WO2015036917A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036917A2 (en) * 2013-09-10 2015-03-19 MockV Solutions Methods and kits for quantifying the removal of mock virus particles from a purified solution
US20220026440A1 (en) * 2018-11-14 2022-01-27 Nissan Chemical Corporation Container and method for storing, pretreating, and analyzing biomaterial
EP4112735A4 (en) * 2020-02-28 2023-09-06 Asahi Kasei Medical Co., Ltd. Method for evaluating viral clearance performance
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
CN118465260B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 测定逆转录病毒包膜蛋白elisa方法的建立及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814442A (en) * 1994-06-10 1998-09-29 Georgetown University Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
US20100297604A1 (en) * 2006-06-09 2010-11-25 Xing-Xiang Li Methods and reagents for virus isolation and detection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002026A1 (en) * 1986-09-08 1988-03-24 Applied Biotechnology, Inc. Empty viral capsid vaccines
US5173399A (en) * 1988-06-10 1992-12-22 Abbott Laboratories Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests
AU631159B2 (en) * 1988-11-14 1992-11-19 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Parvovirus capsids
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO2001072964A2 (en) 2000-03-27 2001-10-04 Smithkline Beecham Corporation Detection of viable agents
EP1170367A1 (en) * 2000-06-27 2002-01-09 Bayer Ag BVDV virus-like particles
US20040002058A1 (en) * 2001-06-21 2004-01-01 Uab Research Foundation Chimeric capsid proteins and uses thereof
US7041444B2 (en) * 2003-01-14 2006-05-09 Washington University Murine calicivirus
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
US20070184068A1 (en) * 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
EP2198020B1 (en) * 2007-09-14 2016-04-13 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0803068D0 (en) * 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
TW201028433A (en) * 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
US9744228B2 (en) * 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2015036917A2 (en) * 2013-09-10 2015-03-19 MockV Solutions Methods and kits for quantifying the removal of mock virus particles from a purified solution

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814442A (en) * 1994-06-10 1998-09-29 Georgetown University Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
US20100297604A1 (en) * 2006-06-09 2010-11-25 Xing-Xiang Li Methods and reagents for virus isolation and detection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRIMM, D. et al, "Titration of AAV-2 Particles via a Novel Capsil ELISA: Packaging of Genomes Can Limit Production of Recombinant AAV-2", GENE THERAPY. 1999, vol. 6, no. 7, pp 1322 - 1330 *
Holger Maerz et al., "Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration", Nature Biotechnology, 1996, vol. 14, pages 651-652 *
KUCK, D. et al, "Development of AAV serotype-specific ELISAs using novel monoclonal antibodies", JOURNAL OF VIROLOGICAL METHODS, 2007, vol. 140, no. 1-2, pp 17 - 24 *
WISTUBA A. et al., "Subcellular compartmentalization of adeno-associated virus type 2 assembly", JOURNAL OF VIROLOGY.1997, vol. 71, no. 2, pp 1341 - 1352 *

Also Published As

Publication number Publication date
US10309963B2 (en) 2019-06-04
US20190353656A1 (en) 2019-11-21
WO2015036917A3 (en) 2015-12-03
AU2014320015A1 (en) 2016-03-31
US20150072339A1 (en) 2015-03-12
AU2023229501A1 (en) 2023-09-28
US9632087B2 (en) 2017-04-25
WO2015036917A2 (en) 2015-03-19
US20240085419A1 (en) 2024-03-14
JP2019195333A (ja) 2019-11-14
EP3044339A4 (en) 2017-04-26
CN105899684A (zh) 2016-08-24
JP2016529908A (ja) 2016-09-29
US20170192001A1 (en) 2017-07-06
EP3044339A2 (en) 2016-07-20
AU2021200484A1 (en) 2021-02-25
CN105899684B (zh) 2021-06-11
DK3044339T3 (da) 2019-08-12
EP3044339B1 (en) 2019-05-22
JP6549126B2 (ja) 2019-07-31
AU2023229501B2 (en) 2025-04-03
US11754565B2 (en) 2023-09-12
AU2021200484B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
AU2021200484B2 (en) Methods and kits for quantifying the removal of Mock Virus Particles from a purified solution
Van Der Loo et al. Progress and challenges in viral vector manufacturing
EP3459965B1 (en) Methods of predicting ancestral virus sequences and uses thereof
EP2154147B1 (en) A truncated l1 protein of human papillomavirus 16
CN106479985A (zh) 病毒介导的Cpf1蛋白在CRISPR/Cpf1基因编辑系统中的应用
TWI735433B (zh) 偵測生物污染物之組成物及方法
CN109069616A (zh) 稳定化的可溶性融合前rsv f蛋白
CN105859877A (zh) 一种hpv特异性抗体的制备方法及冻干制剂
CN111729078B (zh) 鸡传染性贫血病毒基因工程疫苗
RU2445357C1 (ru) Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
CN110724695A (zh) 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN120518721B (zh) 一种巨细胞病毒糖蛋白b及其制备方法和应用
EP3250696B1 (en) Stock solution of retrovirus like particles with method
CN120683135A (zh) 嵌合表达新冠病毒rbd蛋白的甲型流感病毒样颗粒及其制备方法和应用
RU2445358C1 (ru) Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN119842809A (zh) 一种hpv中和抗体假病毒及其制备方法和应用
HK40006673B (en) Methods of predicting ancestral virus sequences and uses thereof
HK40006673A (en) Methods of predicting ancestral virus sequences and uses thereof
GP120 Patent reports
Affinity Tagging Retrovirus Vectors with a Metal

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME TO READ MOCKV SOLUTIONS LLC

PC Assignment registered

Owner name: CYGNUS TECHNOLOGIES, LLC

Free format text: FORMER OWNER(S): MOCKV SOLUTIONS LLC